Clinical Trial

Hyperpolarized 13C MRI for Cancer Immunotherapy

Study acronym: DNPSPIO
Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 30, 2023 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The investigators aim to develop an advanced imaging platform, such as dynamic nuclear polarization (DNP) 13C-MRI, MR fingerprinting (MRF) and MR Relaxometry, which combines with traditional anatomical contrast CT, MRI and PET, and integrate blood/urine metabolomics methods. A comprehensive strategy to thoroughly analyze the immune activation of spleen pattern, microstructure, cell density, red blood cell iron content, immune cell glycolysis and metabolic flow rate.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05805358
Lead Sponsor Chang Gung Memorial Hospital
Collaborators: National Science and Technology Council
Conditions Gynecologic Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Enrollment 90 participants
Start Date 2023-11-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-30